-
公开(公告)号：EP2225233A1
公开(公告)日：2010-09-08
申请号：EP08863529.7
申请日：2008-12-19
申请人： Glaxo Group Limited
IPC分类号： C07D413/04 , C07D217/06 , C07D217/22 , C07D217/16 , A61P37/00 , A61P17/00 , A61K31/4725 , C07D413/14
CPC分类号： C07D217/06 , C07D217/16 , C07D217/22 , C07D413/04
摘要： The present application discloses oxadiazote based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heleroaryl ring; B is selected from one of the following; Formulae: (a) (b) (c)
-
公开(公告)号：EP2164837A1
公开(公告)日：2010-03-24
申请号：EP08760915.2
申请日：2008-06-12
申请人： Glaxo Group Limited
发明人： GIANOTTI, Massimo , LOVELL, Peter, John , SERI, Catia , TEHAN, Benjamin, Gerald , HEER, Jag, Paul
IPC分类号： C07D295/185 , A61K31/496 , A61P25/18
CPC分类号： C07D295/185
摘要： The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof for treating diseases and conditions mediated by positive allosteric modulation of the G- protein coupled metabotropic subtype 5 receptor (mGluR5), such as neurological and psychiatric disorders, for example schizophrenia. In addition, the invention relates to compositions containing the derivatives and processes for their preparation.
摘要翻译： 本发明提供了式（I）化合物或其药学上可接受的盐，用于治疗由G-蛋白偶联的代谢型亚型5受体（mGluR5）的正变构调节介导的疾病和病症，例如神经病学和精神病学疾病，例如精神分裂症 。 此外，本发明涉及含有该衍生物的组合物及其制备方法。
-
公开(公告)号：EP2225233B1
公开(公告)日：2013-09-04
申请号：EP08863529.7
申请日：2008-12-19
申请人： Glaxo Group Limited
IPC分类号： C07D413/04 , A61K31/4725 , A61P37/00 , A61P17/00
CPC分类号： C07D217/06 , C07D217/16 , C07D217/22 , C07D413/04
-
4.发明公开
公开(公告)号：EP2220077A1
公开(公告)日：2010-08-25
申请号：EP08863729.3
申请日：2008-12-19
申请人： Glaxo Group Limited
发明人： HEER, Jag, Paul , HEIGHTMAN, Thomas, Daniel , HURST, David, Nigel , JOHNSON, Christopher, Norbert , SKIDMORE, John , WALL, Ian, David
IPC分类号： C07D413/04 , C07D413/14 , A61K31/553 , A61P37/00
CPC分类号： C07D413/04 , C07D413/14
摘要： The present invention relates to novel oxadiazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof thereof. Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of conditions or disorders which are mediated via the S1 P1 receptor. In particular the compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependant diabetes.
-
公开(公告)号：EP2271643A1
公开(公告)日：2011-01-12
申请号：EP09738180.0
申请日：2009-04-29
申请人： Glaxo Group Limited
发明人： ELDRED, Colin, David , HEER, Jag, Paul , HEIGHTMAN, Thomas, Daniel , SKIDMORE, John , WANG, Hailong
IPC分类号： C07D413/04 , C07D413/14 , A61K31/4725 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P3/10 , A61P19/02 , A61P29/00 , A61P9/10 , A61P11/06 , A61P17/06
CPC分类号： C07D413/04 , C07D413/14
摘要： The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
-
6.发明公开
公开(公告)号：EP2222671A1
公开(公告)日：2010-09-01
申请号：EP08865412.4
申请日：2008-12-19
申请人： Glaxo Group Limited
IPC分类号： C07D413/04 , C07D217/06 , C07D217/22 , C07D217/16 , A61P37/00 , A61P17/00 , A61K31/4725 , C07D413/14
CPC分类号： C07D217/22 , C07D217/06 , C07D217/16 , C07D413/04 , C07D413/14
摘要： The present application discloses oxadiazole based compounds of Formula (I) active o sphingosine-1-phosphate (S1 P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; B is selected from one of the following; Formulae: (a) (b) (c)
摘要翻译： 本申请公开了具有活性的1-磷酸鞘氨醇（S1P）的式（I）的基于恶二唑的化合物，特别可用于治疗红斑狼疮。 A是苯基或5或6元杂芳基环; B选自以下之一; 公式：（a）（b）（c）
-
公开(公告)号：EP2271643B1
公开(公告)日：2012-08-15
申请号：EP09738180.0
申请日：2009-04-29
申请人： Glaxo Group Limited
发明人： ELDRED, Colin, David , HEER, Jag, Paul , HEIGHTMAN, Thomas, Daniel , SKIDMORE, John , WANG, Hailong
IPC分类号： C07D413/04 , C07D413/14 , A61K31/4725 , A61P35/00 , A61P37/00 , A61P37/06 , A61P37/08 , A61P3/10 , A61P19/02 , A61P29/00 , A61P9/10 , A61P11/06 , A61P17/06
CPC分类号： C07D413/04 , C07D413/14
摘要： The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
-
8.发明公开OXADIAZOLE DERIVATIVES FOR USE AS S1P1 AGONISTS IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS 审中-公开恶二唑AS S1P1激动剂自身免疫和炎性疾病的治疗
公开(公告)号：EP2222670A1
公开(公告)日：2010-09-01
申请号：EP08864758.1
申请日：2008-12-19
申请人： Glaxo Group Limited
IPC分类号： C07D413/04 , A61K31/4245 , A61P37/00
CPC分类号： C07D413/04
摘要： The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.
-
公开(公告)号：EP2222669A1
公开(公告)日：2010-09-01
申请号：EP08864021.4
申请日：2008-12-19
申请人： Glaxo Group Limited
发明人： DEMONT, Emmanuel, Hubert , HEER, Jag, Paul , HEIGHTMAN, Thomas, Daniel , HURST, David, Nigel , JOHNSON, Christopher, Norbert , SKIDMORE, John , WALL, Ian, David , WITHERINGTON, Jason
IPC分类号： C07D413/04 , C07D413/14 , C07D223/16 , C07D267/14 , C07D271/06 , A61P37/00 , A61P17/00 , A61K31/55
CPC分类号： C07D223/16 , C07D267/14 , C07D271/06 , C07D413/04 , C07D413/14
摘要： The present application discloses oxadiazole based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; R1 is up to two substituents independently selected from halogen, C(1-3)aIkoxy, C(1-3)flyoroalkyl, cyano, optionally substituted phenyl. C(1-3)fluoroalkoxy. C(1-6)alkyl and C(3-6)Cyctoalkyl; R2 is hydrogen, halogen or C(1-4)alkyl; B is a 7 membered saturated ring selected from the following: Formulae (a) (b) (c) R3 is hydrogen or (CH2)1-4MCO2H; R4 is hydrogen or C(1-3)alkyl optionally interrupted by oxygen;
-
公开(公告)号：EP2222669B1
公开(公告)日：2013-08-21
申请号：EP08864021.4
申请日：2008-12-19
申请人： Glaxo Group Limited
发明人： DEMONT, Emmanuel, Hubert , HEER, Jag, Paul , HEIGHTMAN, Thomas, Daniel , HURST, David, Nigel , JOHNSON, Christopher, Norbert , SKIDMORE, John , WALL, Ian, David , WITHERINGTON, Jason
IPC分类号： C07D413/04 , C07D413/14 , C07D223/16 , C07D267/14 , C07D271/06 , A61P37/00 , A61P17/00 , A61K31/55
CPC分类号： C07D223/16 , C07D267/14 , C07D271/06 , C07D413/04 , C07D413/14
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.014 秒)
